Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 299Observational 66Expanded_access 1

Sponsor

Cancer Type

Dermatologic 21Gastrointestinal 4Thoracic 3Gynecologic 3Genitourinary 3CNS 3Sarcoma 1Head & Neck 1Breast 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3HER2-positive Breast Cancer 3Sarcoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Triple Negative Local Advanced Breast Cancer 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic gpNMB Expressing Triple Negative Breast Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Head and Neck Neoplasms 1Glioblastoma 1Colonic Neoplasms 1Chordoma 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

pegilodecakin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × Breast × Clear all
NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡